LL-37 Dosage: A Beginner's Guide to Amounts and Frequency
LL-37 is a naturally occurring human peptide studied for its role in immune defense and tissue repair. Community discussions typically place doses in the range of 50 to 200 mcg per injection, most often run in short cycles of two to four weeks. Because human safety data is limited and dosing is measured in micrograms, precision and consistent tracking matter more here than with most other research peptides.
What Is LL-37 and Where Does It Come From?
LL-37 is the only known member of the cathelicidin family of antimicrobial peptides found in humans. The body produces it naturally in neutrophils, epithelial cells of the skin and gut, and other immune-active tissues.
The name "LL-37" describes its structure: the peptide begins with two leucine (L) amino acids and contains 37 amino acid residues total.
As a supplement, LL-37 is sold only as a research compound. It is not an approved drug in the United States or most other countries. It is not intended to diagnose, treat, cure, or prevent any condition.
How Is LL-37 Measured and Why Does That Matter?
Unlike many compounds dosed in milligrams, LL-37 is dosed in micrograms (mcg). One microgram is one thousandth of a milligram. That is a very small amount, which means even minor measurement errors translate into relatively large percentage differences.
Most LL-37 sold for research comes as lyophilized (freeze-dried) powder. Before use, it must be reconstituted with bacteriostatic water. The concentration you create at that step determines how much peptide is in each drawn volume. Getting that math right is not optional.
What Dose Amounts Do Researchers and Community Members Discuss?
Published human clinical trials on injectable LL-37 are limited, so most dosing information comes from community sources and preclinical research.
Community-reported subcutaneous doses typically fall in the range of 50 to 200 mcg per injection. Beginners most often start in the 50 to 100 mcg range to assess individual response before adjusting.
These numbers are reference points, not prescriptions. Individual response varies, and no dose has been confirmed as effective or safe for any specific purpose in human trials.
How Often Is LL-37 Typically Dosed?
Once-daily subcutaneous injection is the most common community-reported frequency. Some people describe every-other-day dosing, particularly in the first week or when monitoring for any reaction.
There is no peer-reviewed human data establishing an optimal frequency. Daily dosing is a community convention, not a clinical recommendation.
How Long Do Most Cycles Run?
Because LL-37 interacts directly with immune signaling pathways, community members typically describe short cycles rather than indefinite use. Common cycle lengths cited range from two to four weeks, often followed by a break of equal or greater length before repeating.
Longer or continuous cycles are rarely discussed, partly because long-term human safety data is essentially nonexistent.
Anyone with an autoimmune condition, an inflammatory condition, an active infection, or who is pregnant or breastfeeding should speak with a licensed clinician before considering any research peptide.
What Is the Most Common Route of Administration?
Subcutaneous injection is the route most commonly described in community discussions. Common injection sites include the abdomen and other areas with accessible subcutaneous fat.
Intranasal use is also referenced in some preclinical and community contexts, particularly in connection with respiratory immune studies. This route is less common in general community use and carries its own set of unknowns.
How Do You Calculate Your Dose After Reconstitution?
This step is where most beginners make errors. If you reconstitute 1 mg (1,000 mcg) of LL-37 powder in 2 mL of bacteriostatic water, the resulting concentration is 500 mcg per mL. A 100 mcg dose would then equal 0.2 mL, or 20 units on a standard U-100 insulin syringe.
The math changes with every reconstitution volume, which is why a dedicated calculator helps. The peptide calculator at DoseVault handles this math step by step and lets you log each dose with the exact amount and time. Logging matters because microgram dosing leaves no room for approximation, and a consistent record lets you review your protocol over time.
Frequently Asked Questions
Is LL-37 FDA approved?
No. LL-37 is sold as a research compound and is not approved by the FDA for any human use.
Can LL-37 be taken orally?
Oral bioavailability of peptides like LL-37 is generally considered poor because digestive enzymes break down peptide bonds. Most community use references subcutaneous injection for this reason.
What does LL-37 actually do in the body?
It is studied for antimicrobial activity, modulation of innate immune responses, and involvement in wound healing processes. Claims that it treats or cures any condition are not supported by human clinical evidence.
What concern do community members raise most often?
Immune modulation is the most frequently cited issue, since LL-37 interacts with inflammatory signaling pathways. People with autoimmune conditions are consistently advised to consult a clinician before use.
How should I keep track of what I am doing?
A written log or a purpose-built tracking app both work. The key is recording dose amount, injection site, time, and any observations after each use. Start building your log before your first dose, not after.
Ready to track your protocol with accurate reconstitution math and dose logging? Visit https://dosevault.app to get started.
Related
This article is for general educational purposes only. It does not diagnose, treat, cure, or prevent any condition. Speak with a licensed healthcare professional before using any research compound.